Same-day ablation and WATCHMAN closure for AFib
Part of Heart & circulation clinical trials.
This study tests whether doing a common AFib procedure (radiofrequency ablation) is safe and effective at the same time as closing off the left atrial appendage with the WATCHMAN FLX device. It's for people with nonvalvular atrial fibrillation who are already candidates for both treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have nonvalvular atrial fibrillation (AFib, an irregular heartbeat that is not caused by a heart valve problem)
- Your doctor plans to use the WATCHMAN FLX device to close off a small pouch in your heart (the left atrial appendage) to reduce stroke risk
- Before the procedure, imaging shows the shape of that pouch is right for the device
- You do not have other serious health problems like recent major bleeding, blood clots, or kidney/liver failure
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two ways of closing a small pouch in the heart (the left atrial appendage) to help prevent strokes in people with atrial fibrillation (an irregular heartbeat). One method is less invasive, and the study aims to see if it is as safe and effective as the standard approach.
This study tests if adding a special energy treatment (pulsed field ablation) to a standard heart pouch closure is safe and works better for people with persistent atrial fibrillation who have few symptoms but a high risk of stroke.
This trial is for people who need both a special heart treatment called pulsed field ablation (FARAPULSE) and a device to close off a small pouch in the heart (WATCHMAN FLX Pro or WATCHMAN FLX) to prevent strokes. The study will see how well both procedures work when done together.
This study tests whether combining a heart procedure (catheter ablation) with a device to close the left atrial appendage (LAAO) is safer or better than blood thinners alone for frail patients 75 years or older with atrial fibrillation and high stroke risk. It aims to find a treatment that reduces stroke while lowering bleeding risks.
This study tests whether closing a heart pocket called the left atrial appendage can lower future stroke or other clot-related events in people with atrial fibrillation. It’s mainly for people who have had a prior clot-related event or are at higher risk but may not be good candidates for long-term blood thinners.
This trial tests a new device, the Append System, to close off the left atrial appendage (a small pouch in the heart) in people with atrial fibrillation. The goal is to reduce stroke risk without needing long-term blood thinners.
Hear when a new Cardiovascular Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.